WALTHAM, Mass., June 27, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $13.50 per share. The shares of TESARO's common stock have been approved for listing on the NASDAQ Global Select Market and are expected to begin trading tomorrow, June 28, 2012, under the symbol "TSRO." All of the shares of common stock are being offered by TESARO. In addition, TESARO has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock to cover over-allotments, if any.
The offering is expected to close on July 3, 2012, subject to customary closing conditions.
Citigroup, Morgan Stanley and Leerink Swann are acting as joint book-running managers for the offering. BMO Capital Markets and Baird are acting as co-managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 27, 2012. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov.
This offering is being made only by means of a prospectus that forms part of the effective registration statement, copies of which may be obtained from: Citigroup, Attention: Prospectus Department, Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, by email at batprospectusdept@citi.com and by phone at 1-800-831-9146; Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com or by phone at 1-866-718- 1649; or Leerink Swann, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by email at Syndicate@Leerink.com or by phone at 1-800-808-7525, Ext. 4814.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About TESARO
TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.
The TESARO, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13456